- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT 2024/25 | 1 | HKEx | ||
| Di | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF INTERIM REPORT 2024/25 | - | HKEx | ||
| EXTRAWELL PHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| Di | EXTRAWELL PHAR (00858): INTERIM REPORT 2024/25 | - | HKEx | ||
| 29.11. | EXTRAWELL PHAR (00858): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2024 | 3 | HKEx | ||
| 19.11. | EXTRAWELL PHAR (00858): PROFIT ALERT | - | HKEx | ||
| 14.11. | EXTRAWELL PHAR (00858): DATE OF BOARD MEETING | 1 | HKEx | ||
| 15.10. | EXTRAWELL PHAR (00858): COMPLETION OF MAJOR TRANSACTION IN RELATION TO THE EXTENSION OF LOAN AGREEMENT AND PROVISION OF FINANCIAL ASSISTANCE | - | HKEx | ||
| 15.10. | EXTRAWELL PHAR (00858): POLL RESULTS OF THE SPECIAL GENERAL MEETING HELD ON 15 OCTOBER 2024 | 1 | HKEx | ||
| 26.09. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF CIRCULAR CONTAINING NOTICE OF SPECIAL ... | - | HKEx | ||
| 26.09. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF CIRCULAR CONTAINING NOTICE OF SPECIAL ... | - | HKEx | ||
| 26.09. | EXTRAWELL PHAR (00858): NOTICE OF SPECIAL GENERAL MEETING | 1 | HKEx | ||
| 26.09. | EXTRAWELL PHAR (00858): FORM OF PROXY FOR SPECIAL GENERAL MEETING TO BE HELD ON TUESDAY, 15 OCTOBER 2024 AT 11:00 A.M. | - | HKEx | ||
| 26.09. | EXTRAWELL PHAR (00858): MAJOR TRANSACTION IN RELATION TO THE EXTENSION OF LOAN AGREEMENT AND PROVISION OF FINANCIAL ASSISTANCE AND NOTICE OF SPECIAL GENERAL ... | - | HKEx | ||
| 13.09. | EXTRAWELL PHAR (00858): DELAY IN DESPATCH OF CIRCULAR IN RELATION TO THE MAJOR TRANSACTION EXTENSION OF LOAN AGREEMENT AND PROVISION OF FINANCIAL ASSISTANCE | - | HKEx | ||
| 23.08. | EXTRAWELL PHAR (00858): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 23 AUGUST 2024 | 1 | HKEx | ||
| 12.08. | EXTRAWELL PHAR (00858): RETIREMENT OF AUDITOR AND WITHDRAWAL OF RESOLUTION AT THE ANNUAL GENERAL MEETING TO BE HELD ON 23 AUGUST 2024 | 1 | HKEx | ||
| 30.07. | EXTRAWELL PHAR (00858): MAJOR TRANSACTION EXTENSION OF LOAN AGREEMENT AND PROVISION OF FINANCIAL ASSISTANCE | - | HKEx | ||
| 26.07. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF ANNUAL REPORT 2024, CIRCULAR CONTAINING ... | 1 | HKEx | ||
| 26.07. | EXTRAWELL PHAR (00858): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - NOTICE OF PUBLICATION OF ANNUAL REPORT 2024, CIRCULAR CONTAINING ... | 2 | HKEx | ||
| 26.07. | EXTRAWELL PHAR (00858): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx |
Seite:
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| IONIS PHARMACEUTICALS | 33,930 | -0,73 % | IONIS PHARMACEUTICALS INC - 8-K, Current Report | ||
| CSPC PHARMA | 0,600 | 0,00 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - SYS6005 (ANTIBODY-DRUG CONJUGATE) OBTAINS CLINICAL TRIAL APPROVAL | ||
| ACADIA PHARMACEUTICALS | 16,125 | -0,37 % | Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview | SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the third quarter ended September 30, 2024.
"The success of Acadia's two growing... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 0,875 | +0,81 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Triggers Interim Analysis in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia | - Study Reaches Pre-Specified Threshold of 60 Events (Deaths) Initiating the Interim Analysis - - REGAL Independent Data Monitoring Committee to Perform Interim Analysis in January 2025 - - Company... ► Artikel lesen | |
| MADRIGAL PHARMACEUTICALS | 288,80 | -2,40 % | Arrowhead Pharma und Madrigal gehen steil: Zwischen Adipositas- und Übernahmefantasie | Die Biotechnologie-Branche bietet viele spannende Storys. Einen aussichtsreichen Aktienkorb mit 14 verschiedenen Titeln bildet der Biotech Supertrends Index ab. Zuletzt sorgten im Index vor allem die... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,330 | -0,29 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE in Japan | CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| OPUS GENETICS | 1,028 | +7,76 % | Opus Genetics, Inc.: Opus Genetics Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Trial of APX3330 in Diabetic Retinopathy | Agreement Reached on Primary Endpoint and Phase 3 Trial Design Oral APX3330 is a Late-Stage Clinical Asset Available for Partnering FARMINGTON HILLS, Mich., Dec. 19, 2024 (GLOBE NEWSWIRE) --... ► Artikel lesen | |
| ENZON PHARMACEUTICALS | 0,092 | -22,46 % | ENZON PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | ||
| VIRACTA THERAPEUTICS | 0,226 | +4,63 % | Viracta Therapeutics, Inc.: Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update | - Reprioritized resources to reduce costs and enhance focus on Nana-val's development program in relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) - - On track to report... ► Artikel lesen | |
| ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Acetaminophen and Hydrocodone Tablets | Northvale, New Jersey--(Newsfile Corp. - December 2, 2024) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products... ► Artikel lesen | |
| SAVARA | 3,100 | -0,64 % | Savara (NASDAQ:SVRA) Now Covered by Analysts at Wells Fargo & Company | ||
| GALECTIN THERAPEUTICS | 0,900 | -8,63 % | Galectin Therapeutics Inc.: Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH | In the pre-specified per-protocol population, belapectin showed a statistically significant reduction (p-value While there was a favorable trend for incidence of varices in the primary end point intent-to-treat... ► Artikel lesen | |
| BIODEXA PHARMACEUTICALS | 3,900 | -0,51 % | Biodexa Pharmaceuticals PLC: Result of General Meeting | November 22, 2024 Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") Result of General Meeting Biodexa Pharmaceuticals PLC ("Biodexa" or the "Company") (NASDAQ: BDRX), a clinical stage biopharmaceutical... ► Artikel lesen | |
| SCICLONE PHARMACEUTICALS | - | - | SCICLONE PHARMA (06600): (1) PROPOSAL FOR THE PRIVATISATION OF SCICLONE PHARMACEUTICALS (HOLDINGS) LIMITED BY SILVER PEGASUS INVESTMENT LIMITED BY WAY ... | ||
| NOVABAY PHARMACEUTICALS | 0,080 | 0,00 % | NovaBay Pharmaceuticals, Inc. - 8-K, Current Report |
EXTRAWELL PHARMACEUTICAL HOLDINGS LTD gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXTRAWELL PHARMACEUTICAL HOLDINGS LTD finden Sie auf Wallstreet Online.
